» Articles » PMID: 9759797

Immunohistochemical Characterization of Cellular Infiltrate in Nasal Polyp from Aspirin-sensitive Asthmatic Patients

Overview
Date 1998 Oct 6
PMID 9759797
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The immunopathologic mechanism of nasal polyp in aspirin-sensitive asthma remains to be further defined.

Objective: To characterize the features of the inflammatory cellular infiltrate in the nasal polyp tissue from aspirin-sensitive asthmatic patients.

Methods: We have taken nasal polyp tissue during nasal polyp resection from 13 aspirin-sensitive asthma, 6 allergic, and 12 non-allergic subjects. Immunohistochemistry was employed to stain and enumerate the individual inflammatory cell types using monoclonal antibodies against tryptase (AA1) to identify mast cells, against secreted forms of eosinophil cationic protein (EG2), to identify activated eosinophils, against neutrophil elastase (NE) for neutrophils and against T cell surface markers (CD3) to identify total T cells.

Results: There were no significant differences in AA1 + cells among three groups (P>.05). EG2 + cells tended to be higher in ASA-sensitive asthmatic patients than in allergic and non-allergic subjects, but no statistical significance was observed. NE+ cells were found in most subjects of the three groups and their numbers were significantly higher in allergic subjects than in aspirin-sensitive asthma (P<.05). Some patients had CD3+ cells with no statistical significance among the three groups. Significant correlation was found in numbers between NE+ cell and AA1+ cell (r=.44, P=.01), and between NE+ cell and EG2+ cell (r=.40, P=.02).

Conclusion: These findings suggested that major effector cells such as mast cells and eosinophils might be placed in the center of the inflammatory response of nasal polyps, regardless of their association with aspirin sensitivity.

Citing Articles

Emerging Biomarkers Beyond Leukotrienes for the Management of Nonsteroidal Anti-inflammatory Drug (NSAID)-Exacerbated Respiratory Disease.

Rhyou H, Nam Y, Park H Allergy Asthma Immunol Res. 2022; 14(2):153-167.

PMID: 35255534 PMC: 8914608. DOI: 10.4168/aair.2022.14.2.153.


Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.

Sehanobish E, Asad M, Barbi M, Porcelli S, Jerschow E Front Immunol. 2021; 12:695815.

PMID: 34305932 PMC: 8297972. DOI: 10.3389/fimmu.2021.695815.


Potential Biomarkers for NSAID-Exacerbated Respiratory Disease.

Park H, Choi Y, Jung C, Park H Mediators Inflamm. 2017; 2017:8160148.

PMID: 28852271 PMC: 5568600. DOI: 10.1155/2017/8160148.


Eosinophils and Mast Cells in Aspirin-Exacerbated Respiratory Disease.

Steinke J, Payne S, Borish L Immunol Allergy Clin North Am. 2016; 36(4):719-734.

PMID: 27712766 PMC: 5116300. DOI: 10.1016/j.iac.2016.06.008.


Galectin-10 is released in the nasal lavage fluid of patients with aspirin-sensitive respiratory disease.

Negrete-Garcia M, Jimenez-Torres C, Alvarado-Vasquez N, Montes-Vizuet A, Velazquez-Rodriguez J, Jimenez-Martinez M ScientificWorldJournal. 2012; 2012:474020.

PMID: 22654612 PMC: 3361262. DOI: 10.1100/2012/474020.